Suntory Limited

Mita Industrial Co., Ltd.

Daiichi Sankyo Company, Limited

Asubio Pharma Co. Ltd.

Nippon Paint Compnay, Ltd.

Meiji Co., Ltd.

Ausbio Pharma Co., Ltd.

Mikunikikaj Co. Ltd.

Yasuhiro Hayashi

Hidekazu Inoue

Hidenobu Murafuji

Tetsuo Shimamoto

Shigeru Nishiyama

Naoki Higuchi

Masayuki Saitoh

Shinjiro Niwata

Yoshinobu Kiso

Hisaichi Muramoto

Naoki Yamane

Akira Sakamoto

Hitoshi Hori

Yoshihisa Yamashita

Koji Yamamoto

Seiko Inoue, Legal Representative

Katsuji Hayata

Eiji Tatsumi

Toyoko Katayama

Takashi Nakatsuka

Toshiyuki Tomoo

Yutaka Sekiba

A packaged product which comprises a solid object and a packaging that seals and holds the solid object, wherein a replacement gas is contained in a space sealed by the packaging when the packaging is sealed and wherein the solid object has absorbed a part of or all of the replacement gas.

Packaged solid object and method for manufacturing thereof

To provide thienopyrazole derivatives inhibiting PDE 7 selectively, and therefore, enhance cellular cAMP level. Consequently, the compound is useful for treating various kinds of disease such as allergic diseases, inflammatory diseases or immunologic diseases. The compound is thienopyrazole compound represented by the following formula (I): [wherein, especially, Ris a cyclohexyl, a cycloheptyl group or a tetrahydropyranyl group; Ris methyl; Ris a hydrogen atom; and Ris a group: &#x2014;CONRR(in which any one of Rand Ris a hydrogen atom)].

Thienopyrazole derivative having PDE7 inhibitory activity

A compound, or its salt, or a solvate thereof having a cPLAinhibiting activity having the formula (I): or a pharmaceutical composition, cPLAinhibitor and inhibitors of various lipid mediator production containing the same as active ingredients.

[object Object]

To provide the compounds inhibiting PDE 7 selectively, and therefore, enhance cellular cAMP level. Consequently, the compound is useful for treating various kinds of disease such as allergic disease, inflammatory disease or immunologic disease. The compound is pyridinylpyrazolo-pyrimidinone compound represented by the following formula (IA) or (IB): especially, Ris cyclohexyl or cycloheptyl group, Ris methyl; Ris a group: &#x2014;NRRor &#x2014;S(O)R;hydrogen atom; nitro group; cyano group; a halogen atom; heteroaryl group; and Ris methoxy or ethoxy group.

Pyridinylpyrazolopyrimidinone derivatives as PDE 7 inhibitors

The present invention provides the compounds inhibiting PDE 7 selectively, and therefore, enhances cellular cAMP level. Consequently, the compound is useful for treating various kinds of disease such as allergic disease, inflammatory disease or immunologic disease. The compound is imidazotriazinone compound represented by the following formula (IA) or (IB): especially, R1 is cyclohexyl group, R2 is methyl group; R3 is a hydrogen atom; nitro group; cyano group; a halogen atom; heteroaryl group; substituted or unsubstituted C1-C6 alkyl group; substituted or unsubstituted C2-C6 alkenyl group; saturated or unsaturated heterocycloalkyl group which is substituted or unsubstituted; a group: &#x2014;NR5R6, &#x2014;C(O)R7, &#x2014;SO2R7, &#x2014;OR8, &#x2014;NR8COR7, &#x2014;NR8S02R7; A is CR4; and B is CH. 

Imidazotriazinone derivatives as PDE 7 (phosphodiesterase 7) inhibitors

In a method of producing an oil-in-water type emulsion containing an internally crosslinked fine resin particle, the fine resin particle is encapsulated in an emulsion particle having an average particle diameter of 0.02 to 0.3 &#x3bc;m. The method includes a step of undergoing phase transition from a water-in-oil type emulsion (Y) which includes a resin (A) having a cationic group or an anionic group, an acid or a base (B) neutralizing 20 to 150 mole percent of the cationic group or the anionic group in the resin (A), an internally crosslinked fine resin particle (C), having an average particle diameter of 0.01 to 0.2 &#x3bc;m, dispersed in an oil phase and an aqueous medium (D) to an oil-in-water type emulsion (Z) by adding the aqueous medium (D) further to the water-in-oil type emulsion (Y).

Method of producing oil-in-water type emulsion containing internally crosslinked fine resin particle, oil-in-water type emulsion containing internally crosslinked fine resin particle, cation electrodeposition coating composition and substance coated

Pyrazolopyrimidinone derivatives expressed by the following general formula (IA) or (IB): where the symbols are as disclosed in the specification, are provided as desired compounds. These compounds selectively inhibiting PDE7, thereby increasing the intracellular cAMP level and inhibiting the activation of T cells. Thus, these compounds are useful for prevention and treatment of various allergic diseases and inflammatory or immunological diseases.

1,3,5-trisubstituted-5-phenyl and 5-pyridyl pyrazolopyrimidinone derivatives having PDE7 inhibiting action

1-aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase inhibitor

Amount of sub-micron particles in fluid such as ultra pure water classified each range of particle dimensions are detected by a simple apparatus in which a light beam from a coherent light source( ) is converged ( ) in such a manner that the light beam is focused in a stream ( ) of particle-containing fluid, the light passed through the stream and diffracted by the particles is received by a photo-detector ( ) which is positioned at an opposite side of the coherent light source with respect to the stream and substantially on an optical axis of the light beam, so that the number of particles in the stream is distinguished into plural ranges according to each frequencies of the signals emitted from the photo-detector and counting each numbers of the particles contained the ranges.

Method and apparatus for monitoring sub-micron particles

A 1-cycloalkyl-1,8-naphthylidin-4-one derivative having the formula (I):

1-cycloalkyl-1,8-naphthyridin-4-one derivative as type IV phosphodiesterase inhibitor

A 1-aryl-1,8-naphthylidin-4-one derivative having the formula (I):

A cleaner for cleaning the nozzle portion of a powder filling apparatus for filling a container with powder by equally evacuating the inside and the outside of the container, and dropping powder through the nozzle portion into the container simultaneously with raising the pressure outside the container is provided. The cleaner includes a cleaning head having a cleaning chamber therein for enclosing the nozzle portion airtightly when the cleaning head is fitted to the nozzle portion; a gas passage disposed in the cleaner head for allowing compressed air to flow therethrough so as to spurt the compressed air to the nozzle portion; and an exhaust passage for allowing powder flowing down in the cleaning chamber together with the compressed air spurted to the nozzle portion to be discharged together with the compressed air.

Powder filling apparatus and a method for filling a container with powder

A powder charging apparatus includes a low pressure chamber for accommodating a container to be charged with powder. The low pressure chamber is separable into an upper section and a lower section. A pressure reducer reduces the pressures in the low pressure chamber and the container at the same time. A pressure riser increases the pressure in the low pressure chamber. A powder supplier allows a predetermined quantity of powder to fall into the container under a difference in the pressures between inside and outside the container. The powder supplier includes a hopper having an outlet port. The container has an inlet neck portion engageable with a nozzle secured to the low pressure chamber. The nozzle is connected to the outlet port of the hopper. A buffering member is disposed at a space from the nozzle.

Powder charging apparatus

A dipeptide derivative having the formula (I):

Growing community of inventors

Osaka, Japan

Yasuhiro Hayashi